Shopify Shares Rise as Black Friday Sales Surge
By Adriano Marchese
Shopify shares rose in early trading Monday after the company said it saw strong growth in sales during the key Black Friday period.
At 10:01 a.m. ET, shares trading in Toronto were 4.7% higher at 100.75 Canadian dollars ($73.87).
The Canadian ecommerce platform said Saturday that its merchants drove a 22% increase in sales over last year, reaching $4.1 billion in sales from businesses worldwide.
Shopify said that among the top categories for deal-seekers were clothing, personal care and jewelry, with shoppers from U.S., U.K. and Canada leading the charge as top-selling countries.
It said that 15% of all orders were made across borders, and that there was a 33% increase in global sales made on its point-of-sale system.
"The world showed up for our merchants, and the excitement is only building, with Cyber Monday still to come," President Harley Finkelstein said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 27, 2023 10:29 ET (15:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track